Phase l/ll study of adjuvant chemotherapy (TC therapy) after concurrent chemoradiation in cervical cancer with lymphadenopathy

Phase l/ll study of adjuvant chemotherapy (TC therapy) after concurrent chemoradiation in cervical cancer with lymphadenopathy - Phase l/ll study of TC therapy after CCRT in cervical cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004897

Enrollment

Registered

2011-01-19

Start date

2011-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical cancer with lymphadenopathy

Interventions

TC therapy after CCRT No adjuvant chemotherapy after CCRT

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients with FIGO Stage lB2 - lVA of cervical carcinoma and who had lymphadenopathy (N=1) were eligible. No previous chemotherapy or radiotherapy was allowed. Other eligibility criteria include age under 75 years old, Easttern Cooperation Oncology Group (ECOG) performance status score 0-1, blood cell counts, serum level of bloody urea nitrogen, creatinine, bilirubin within normal ranges, and normal cardiovascular function. The criterion for malignancy on positron emission tomography computed tomography (PET/CT) and magnetic resonance imaging (MRI) was a pelvis or para-aortic lymph node with short-axis dimension > 1cm or SUV > 3.

Exclusion criteria

Exclusion criteria: severe complications

Design outcomes

Primary

Measure	Time frame
PFS, tixicity	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026